CASC2 and central nervous system cancer: Downregulation of CASC2 in glioma tissue was showed by Wang et al. [20] in a limited sample of 24 patients, while Liao et al. revealed CASC2 playing a role in modulating glioma temozolomide (TMZ) chemoresistance in 57 patient samples [22].